| Nov | 2006 | Establishment of JapanBridge, Inc. |
| Jun | 2007 | Cooperation Agreement with Kyowa Hakko Kogyo Co., Ltd. in oncology |
| Jan | 2008 | Establishment of Medical & Scientific Advisory Board |
| May | 2008 | License Agreement with ProStrakan for exclusive rights to Sancuso® in Japan, China, and other Asian territories |
| Sep | 2008 | Company name changed to Solasia Pharma K.K. |
| Apr | 2009 | Corporate office move to Shiodome Building (Tokyo) |
| Jun | 2009 | Filing of Clinical Trial Application (CTA) for SP-01 (Sancuso®) in China |
| Jul | 2009 | Completion of SP-01 (Sancuso®) Japanese Phase 1 study |
| Feb | 2010 | License Agreement with Kyowa Hakko Kirin Co., Ltd. for the sublicense of Sancuso® in Taiwan, Hong Kong, Singapore & Malaysia |
| Mar | 2011 | License Agreement with ZIOPHARM Oncology for exclusive rights to darinaparsin in Japan, China, and other Asian territories |
